Despite cervical cancer being virally driven—a characteristic that theoretically makes it highly susceptible to immunotherapy—treatments have shown durable but limited responses. This surprising gap between scientific expectation and clinical reality is driving research into novel combinations, such as immunotherapy plus antibody-drug conjugates (ADCs), to improve efficacy.
To increase uptake, the HPV vaccine should be administered at age nine and framed as a standard childhood cancer vaccine, not one tied to sexual development. This reframing removes a common point of parental hesitation and emphasizes its primary role in cancer prevention, as four out of five people will get HPV in their lifetime.
The increase in cervical cancer incidence among younger women may be an unintended consequence of updated screening guidelines. The move away from annual Pap smears to less frequent, HPV-based testing has disrupted the routine of regular GYN visits, potentially reducing early detection and contributing to a rise in cases.
While the antibody-drug conjugate (ADC) Tivdac offers a new treatment avenue, it introduces significant logistical hurdles. The requirement for a specialist eye exam at every single visit creates a major access barrier for clinics without integrated ophthalmology services, highlighting how non-clinical factors can limit the real-world application of effective drugs.